Dimerix is GO

Wanted to go with "Thunderbirds are GO", but though it was best to stick with Dimerix.

With DXB being oversubscribed by $2 million (after allocations were scaled back), I think we are all very pleased to know that DXB is now free of any financial burden and can confidently proceed into Phase 2B with their lead compound DMX-200. After the funds were confirmed last week a few here on HC speculated at how valuable DXB will become? Only time will tell whether DXB will be worth more or less than VLA's $500 million take over offer.

For now I'm curious to get opinions on how others think DMX-200 will be developed/marketed?

I'm no doctor so please correct me if I'm inaccurate, but from what I understand DXB is looking to develop DMX-200 on 2 fronts:

1) Phase 2B trial of DMX-200 for rare kidney disease FSGS which will start before end March 2018, and

2) Phase 2B trial of DMX-200 for Diabetic Nephropathy (think I read somewhere that this is now 2019??).

So what do you think the plan is?

As initial/final results come in for FSGS, does DXB do a deal using Diabetic Nephropathy as an upside carrot (as the results from Phase 2A where positive, albeit from a small test group), or can they do a deal for FSGS only and continue separately with Diabetic Nephropathy?

Thoughts?

Cheers
Pies